Why More Young Men Have Erectile Dysfunction in 2026 ?
The rise in erectile dysfunction among younger men doesn't point to one neat cause. It looks more like a traffic jam,...
Product Overview
Tabrecta (Capmatinib) is an oral medication used for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) that is positive for MET exon 14 alterations. It works as a selective MET inhibitor, targeting the underlying genetic mutations that drive the cancer's growth.
Indications
Tabrecta is indicated for the treatment of patients with metastatic NSCLC who have a specific genetic mutation known as MET exon 14 alteration.
Dosage and Administration
The recommended dosage of Tabrecta is 150 mg taken orally twice daily, with or without food. It is important to follow your healthcare provider's instructions regarding dosage adjustments and treatment duration.
Possible Side Effects
Common side effects of Tabrecta may include:
- Nausea
- Fatigue
- Edema
- Elevated liver enzymes
- Diarrhea
Precautions
Before taking Tabrecta, inform your healthcare provider about your medical history and any other medications you are taking. Monitor liver function tests regularly during treatment.
Drug Interactions
Tabrecta may interact with other medications. Consult your healthcare provider for a complete list of potential drug interactions.
Storage
Store Tabrecta at room temperature away from moisture and heat. Keep out of reach of children.
Consultation
Always consult your healthcare provider for personalized medical advice and before starting any new treatment.
We do not dispense any prescription medicine without valid and legible prescription written by your local physician. All prescriptions must be presented from a valid verifiable and licensed physician.
We are only able to ship a maximum 90-day supply of your prescription.
All trademarks and registered trademarks are the property of their respective owners. The products mentioned on this website are trademarks of their respective owners and are not owned by or affiliated with this company or any of its associated companies.
